Home/Pipeline/NPT200-11

NPT200-11

Parkinson's Disease

Phase 1Partnered (UCB Pharma), status unclear

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1

Status

Partnered (UCB Pharma), status unclear

Company

Neuropore Therapies

About Neuropore Therapies

Neuropore Therapies is a private biotechnology company pioneering a novel approach to treating neurodegenerative diseases by targeting the toxic protein aggregates that drive conditions like Parkinson's and ALS. The company's platform is built on a deep understanding of protein misfolding and cell-to-cell transmission of pathology, leading to a pipeline of orally available small molecules. While historically advancing programs into clinical trials, Neuropore has strategically partnered key assets and appears to be operating in a focused, non-commercial stage. Its long-term success hinges on clinical validation of its unique mechanism and the ability to secure further development funding or partnerships.

View full company profile

Therapeutic Areas

Parkinson's Disease Amyotrophic Lateral Sclerosis Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active
golexanolone	Umecrine Cognition	Preclinical	Active